Cynata Therapeutics Limited (ASX:CYP) Insider Buys A$20,930.10 in Stock

Cynata Therapeutics Limited (ASX:CYP) insider Paul Wotton bought 69,767 shares of the stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of A$0.30 ($0.19) per share, with a total value of A$20,930.10 ($13,331.27).

Cynata Therapeutics Stock Performance

The company has a market capitalization of $57.60 million, a price-to-earnings ratio of -4.70 and a beta of 0.93.

Cynata Therapeutics Company Profile

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease.